Literature DB >> 7075671

Modulation by prostaglandins of the release of [3H] noradrenaline evoked by potassium and nerve stimulation in the isolated rat heart.

M T Khan, K U Malik.   

Abstract

In the isolated rat heart perfused with Krebs solution and prelabeled with [3H] noradrenaline, we examined the effect of prostaglandins (PG) I2, E2, 6-keto-PGF1 alpha and their precursor, arachidonic acid, on the overflow of tritium elicited by potassium (K+) and by stimulation of cardiac sympathetic nerve plexus. Prostaglandins E2, I2 and arachidonic acid but not 6-keto-PGF1 alpha reduced K+ and nerve stimulation-induced overflow of tritium. Administration of indomethacin, an inhibitor of cyclooxygenase, increased tritium overflow elicited by either K+ or by nerve stimulation. During infusion of indomethacin, the inhibitory effect of both PGE2 and PGI2 on the K+ or nerve stimulation-induced overflow of tritium remained unaltered. In contrast, the effect of arachidonic acid to reduce K+ or nerve stimulation-induced overflow of tritium was abolished by indomethacin, indicating that the fatty acid inhibits release of tritium by its conversion to a product(s) of cyclooxygenase, presumably PGI2 and PGE2. These data suggest that prostaglandins, particularly PGI2 and PGE2 synthesized in the isolated rat heart act on prejunctional sites to modulate release of the adrenergic transmitter.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075671     DOI: 10.1016/0014-2999(82)90238-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Different effects of prostaglandins on adrenergic neurotransmission in atrial and ventricular preparations.

Authors:  L Mantelli; S Amerini; F Ledda
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

2.  Prejunctional prostanoid receptors on cardiac adrenergic terminals belong to the EP3 subtype.

Authors:  L Mantelli; S Amerini; A Rubino; F Ledda
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.